Thursday, October 11, 2018 -- NewsMultiple sclerosis is an autoimmune disease in which the body's own immune system attacks and damages the protective coating around nerve cells.Contributed Author: University of ZurichTopics: Drug Discovery and Development
Wednesday, October 10, 2018 -- The NDA is based on data from the EXPAND study, a randomized, double-blind, placebo-controlled Phase 3 study in 1652 participants living with SPMS.
Wednesday, October 10, 2018 -- Multiple sclerosis is an immune-mediated autoimmune disease of the central nervous system that develops in genetically susceptible individuals and likely requires environmental triggers. The autoantigens and molecular mimics triggering the autoimmune response in multiple sclerosis remain incompletely understood. By using a brain-infiltrating CD4+ T cell clone that is clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have identified guanosine diphosphate (GDP)–l-fucose synthase as an autoantigen that is recognized by cerebrospinal fluid–infiltrating CD4+ T cells from HLA-DRB3*–positive patients. Significant associations were found between reactivity to GDP-l-fucose synthase peptides and DRB3*02:02 expression, along with reactivity against an immunodominant myelin basic protein
Wednesday, October 10, 2018 -- An oral therapy called ibudilast significantly reduced the rate of brain tissue loss in patients with progressive multiple sclerosis, according to the results of a phase II trial.
Thursday, October 11, 2018 -- Surveys were given out to individuals in the Australian Multiple Sclerosis Longitudinal Study between August and December 2016.
Thursday, October 11, 2018 -- Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).
Thursday, October 11, 2018 -- Sexual health is rarely addressed during patient care and research in multiple sclerosis.
Thursday, October 11, 2018 -- Patients were divided into 3 groups: patients not treated in the 3 months before pregnancy, patients treated in the 3 months before pregnancy, and patients treated during pregnancy.
Tuesday, October 09, 2018 -- Higher depressive symptoms in patients with multiple sclerosis was associated with lower employment and processing speed.